新医学2026，Vol.57Issue(9)：927-934,8.DOI:10.12464/j.issn.0253-9802.2026-0752
慢性鼻窦炎复发风险分层与长期管理:2026年中山论坛专家观点
Recurrence risk stratification and long-term management of chronic rhinosinusitis:expert perspectives from the 2026 Zhongshan Forum
摘要
Abstract
Chronic rhinosinusitis(CRS)is a common chronic inflammatory disease in otorhinolaryngology and is characterized by a prolonged course,substantial heterogeneity,a high recurrence risk in selected patients,and a considerable long-term disease burden.With advances in inflammatory endotyping,endoscopic sinus surgery(ESS),biologics,digital follow-up,and artificial intelligence(AI),CRS care is shifting from an experience-based model relying mainly on symptoms and imaging toward integrated management based on risk stratification,precision intervention,and life-course disease control.The 2026 Zhongshan Forum on Chronic Rhinosinusitis discussed difficult-to-treat and recurrent CRS,clinical translation of inflammatory endotypes,sequencing of ESS and biologics,standardized primary care pathways,intelligent follow-up,and translational research priorities.Based on expert discussions from the forum and current guidelines,position papers,and recent evidence,this article proposes that CRS management should strengthen early recurrence-risk assessment,establish a tiered evaluation system,optimize scenario-based sequencing of conventional pharmacotherapy,ESS,and biologics,and promote long-term chronic disease management through regional collaboration and digital tools.The experts emphasized that the future of CRS care lies not in replacing established therapies with a single new technology,but in building an executable,measurable,and scalable system for precision diagnosis and continuous management.关键词
慢性鼻窦炎/鼻息肉/炎症内型/生物制剂/内镜鼻窦手术/人工智能/慢病管理/基层医疗Key words
Chronic rhinosinusitis/Nasal polyps/Inflammatory endotype/Biologics/Endoscopic sinus surgery/Artificial intelligence/Chronic disease management/Primary care分类
医药卫生引用本文复制引用
孙悦奇,杨钦泰,陈枫虹,石照辉,赖银妍,张雅娜,洪海裕,赖明,左可军,史剑波..慢性鼻窦炎复发风险分层与长期管理:2026年中山论坛专家观点[J].新医学,2026,57(9):927-934,8.基金项目
国家自然科学基金(82371114) （82371114）
